All In Biotech

Drug Trial Radar · NCT00546351

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

621

Actual

Start

May 2004

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Oct 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.

Conditions

  • Painful Diabetic Neuropathy

Interventions

  • LacosamideDrug

    50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)
  2. Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)

Locations

101 sites in 15 countries. Site status is shown where the registry gives one.

  • 180

    Vienna, Austria

  • 183

    Vienna, Austria

  • 003

    Antwerp, Belgium

  • 006

    Bonheiden, Belgium

  • 002

    Genk, Belgium

  • 001

    Leuven, Belgium

  • 005

    Merksem, Belgium

  • 004

    Roeselare, Belgium

  • 011

    Pleven, Bulgaria

  • 014

    Plovdiv, Bulgaria

  • 017

    Plovdiv, Bulgaria

  • 019

    Rousse, Bulgaria

  • 012

    Sofia, Bulgaria

  • 013

    Sofia, Bulgaria

  • 015

    Sofia, Bulgaria

  • 016

    Sofia, Bulgaria

  • 210

    Stara Zagora, Bulgaria

  • 010

    Varna, Bulgaria

  • 028

    Brno, Czechia

  • 220

    Chomutov, Czechia

  • 026

    Litoměřice, Czechia

  • 027

    Olomouc, Czechia

  • 024

    Ostrava-Poruba, Czechia

  • 029

    Písek, Czechia

  • 021

    Prague, Czechia

  • 022

    Prague, Czechia

  • 192

    Kuopio, Finland

  • 034

    Lisieux, France

  • 031

    Nevers, France

  • 040

    Bad Saarow, Germany

  • 052

    Beckum, Germany

  • 049

    Berlin, Germany

  • 051

    Berlin, Germany

  • 056

    Berlin, Germany

  • 242

    Berlin, Germany

  • 249

    Berlin, Germany

  • 247

    Bochum, Germany

  • 041

    Hamburg, Germany

  • 045

    Hamburg, Germany

  • 054

    Hamburg, Germany

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.